Partner at Northzone (Web3)
Check size: Not publicly disclosed. Northzone states that the firm invests from Seed through Growth and can remain a partner through pre-IPO; Wendy's current profile labels her personal focus as Early and says she likes to work with founders from as early as seed.
Wendy backs companies that change consumer behavior and expand the economic pie by capturing neglected externalities. She studies technology through people and behavior change, looking for a valuable position in a shifting value chain and a product capable of profound systemic change. Her hypothesis-led process separates factual and emotional evidence, makes assumptions explicit, challenges them through diligence, and still requires a differentiated leap of faith about fund-returning potential.
Lead with the behavior or system that is changing and the externality or value-chain failure the company can capture. State a crisp deal hypothesis, then list the assumptions behind why now, differentiation, go-to-market, incentives, outcomes, and founder-market fit. Bring customer and expert evidence that can challenge those assumptions, acknowledge the subjective risks, and articulate the non-consensus leap by which the company becomes a fund returner.
Idealistic founders pursuing values, willing to confront their limitations, and able to inspire others toward collective progress. She is drawn to interesting human experiences and products that create scalable systemic change in areas such as health, privacy, and education, and she works closely with founders according to their specific needs.
No personal pass list is public. Her hypothesis framework implicitly screens against peer-driven hype, unclear value-chain positioning, assumptions that cannot survive customer or expert diligence, products that do not materially change behavior or outcomes, and teams without a credible leap from an initial product to fund-scale impact.
Translate intuition into a deal hypothesis, enumerate why-now, differentiation, value-chain, go-to-market, and team assumptions, then use expert calls, customer evidence, research, and team challenge to update each assumption and expose bias.
After evidence-based diligence, isolate the non-consensus belief that would let the company reshape its value chain and return the fund; judge its risk explicitly instead of hiding it inside a generic market score.
Look for products that change behavior while turning an ignored social or market cost—such as poor access, administrative burden, privacy loss, or misaligned incentives—into scalable customer and system value.
“I aim to be a true partner in every way that I can, always putting the founder's journey ahead of my own.”
— https://northzone.com/insights/meet-our-first-new-york-partner-wendy-xiao-schadeck-and-other-news-from-us
“We focus our discussions on the level of risk of each of these assumptions.”
— https://northzone.com/insights/hypothesis-led-investing-how-we-institutionalised-gut-driven-investing-and-our-learnings-from-spring-healths-investment-memo
An AI-native medication-access platform can automate authorization and fulfillment, speed treatment, improve adherence, and create a valuable dataset across a fragmented specialty-drug value chain.
AI can give independent service-business owners franchise-like operating leverage by automating lead generation, scheduling, CRM, forms, and payments without taking away their independence.
Early-stage intuition can be made discussable and testable by expressing a deal hypothesis, surfacing its assumptions, gathering factual and emotional evidence, challenging bias, and isolating the leap of faith.
+ 108 more investments. View fund →